Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant High-Dose CTC vs tCTC in High-Risk Breast Cancer
NCT00851110Phase 2Terminated
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide, thiotepa and carboplatin in breast cancer (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Maximum degree of non-hematological toxicity. Started Oct 2004; status: terminated.
02
Drugs
cyclophosphamidethiotepacarboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00851110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00851110.